Eyenovia Invests $50 Million to Build Hyperliquid HYPE Token Treasury Reserve
The Nasdaq-listed biotech firm has unveiled a $50 million investment to establish a treasury reserve of HYPE, the native token of the Hyperliquid blockchain and exchange. This strategic move positions Eyenovia as one of the top validators on the Hyperliquid network—and the first publicly traded U.S. company to hold HYPE tokens in its treasury.
👉 Discover how Hyperliquid is reshaping DeFi
Leadership and Funding Structure
- New Appointment: Hyunsu Jung joins as Chief Investment Officer and board member, spearheading the crypto initiative.
- Funding Mechanism: The capital was raised through a private placement with institutional investors, including convertible preferred stock and warrants. Total potential proceeds could reach $150 million if fully exercised.
From Biotech to Blockchain Innovation
While maintaining its core focus on eye-care technology (e.g., Optejet device targeting FDA approval by late 2025), Eyenovia is pivoting toward blockchain integration:
- Token Acquisition: Plans to acquire 1M+ HYPE tokens for staking rewards and network security.
- Custodial Partnership: Anchorage Digital, a federally regulated custodian, will safeguard the assets.
"Adopting a crypto treasury strategy aligns with our goal to deliver long-term shareholder value,"
— Michael Rowe, CEO of Eyenovia.
Why Hyperliquid?
Hyperliquid’s decentralized exchange has gained traction for its:
- High trading volume.
- Robust DeFi infrastructure.
- Scalability in blockchain applications.
👉 Explore Hyperliquid’s rising dominance
Rebranding and Future Outlook
Eyenovia will transition to "Hyperion DeFi" (ticker: HYPD), merging its biotech legacy with digital finance. Key milestones:
- Continue Optejet development.
- Expand crypto treasury operations.
FAQ Section
Q: How will Eyenovia use the HYPE tokens?
A: Tokens will be staked to earn rewards and validate transactions on Hyperliquid’s network.
Q: Is this investment risky for a biotech company?
A: While novel, the strategy diversifies assets and hedges against inflation, backed by regulated custodianship.
Q: Will Eyenovia abandon its medical projects?
A: No—the Optejet device remains a priority, with FDA submission expected in 2025.
Disclaimer
This content is for informational purposes only and does not constitute financial advice. Cryptocurrencies involve high risks; conduct your own research before investing.